chufangao/CTO huggingface dataset:
Clinical trial NCT04198363: A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
Official title: A Randomized Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral TAK-438 20 mg Compared to Esomeprazole 20 mg Twice Daily in Subjects With Helicobacter Pylori Infection
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 510.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2021-11-01
Completion date: 2021-11-25
Baseline population: Full analysis set (FAS) included all randomized participants who received at least 1 dose of the study drug.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04616027: STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
Official title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT RENAL IMPAIRMENT
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-01-13
Primary completion date: 2022-02-18
Completion date: 2022-02-18
Baseline population: All enrolled participants who received at least one dose of study intervention.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT05984784: A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
Official title: A Phase1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Sponsor: Inmagene LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated because the sponsor believes that results from Cohort 1 will provide reliable information for further development decision. No safety concerns were noted.
Enrollment: 13.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-08-09
Primary completion date: 2024-04-26
Completion date: 2024-04-26
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04745663: Optimizing Preoperative Disinfection of Eyes
Official title: Optimizing Preoperative Disinfection of Eyes
Sponsor: Norwegian University of Science and Technology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Not the expected 2/3 but only 1/3 of conjunctiva samples got bacterial growth. Lack of resources to keep the study going with more participants and over a considerably longer time than anticipated.
Enrollment: 150.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-08
Primary completion date: 2021-04-30
Completion date: 2021-04-30
Clinical trial NCT03122301: Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer
Official title: Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer: A Pilot Randomized Sham-Controlled Trial
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study stopped due to inadequate enrollment.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-01
Primary completion date: 2020-07-01
Completion date: 2020-07-01
Limitations and caveats: This study was terminated due to low enrollment
Clinical trial NCT02856594: Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep
Official title: Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS): A Randomized Placebo-controlled Trial
Acronym: MINDDS
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 469.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-06
Primary completion date: 2022-02-11
Completion date: 2022-02-16
Plan to share individual participant data: YES
IPD time frame: Immediately
IPD access criteria: De-identified data and a data dictionary will be made available upon reasonable request to researchers who provide a methodologically sound proposal and whose use of the data has been approved the study authors. Data will be made available immediately following publication, with no anticipated end date, to achieve the aims specified in the approved proposal. Proposals should be directed to oluwaseun.akeju@mgh.harvard.edu.
Clinical trial NCT03347708: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration
Official title: A Prospective, Randomized, Double-Blinded, Vehicle- and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects With Single-Level, Symptomatic Lumbar Intervertebral Disc Degeneration
Sponsor: DiscGenics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-02-26
Primary completion date: 2022-02-01
Completion date: 2022-11-10
Plan to share individual participant data: NO
Clinical trial NCT01600963: A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis
Official title: A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)
Sponsor: Janssen Infectious Diseases BVBA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: PhIII program revised; TMC207-C210 cancelled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-03-31
Primary completion date: 2016-07-31
Completion date: 2022-11-30
Clinical trial NCT03701321: Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
Official title: Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Drug supply issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-01-25
Primary completion date: 2020-05-28
Completion date: 2020-05-28
Plan to share individual participant data: YES
IPD sharing description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Clinical trial NCT03823391: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Official title: A Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects With Moderate to Severe Rheumatoid Arthritis
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-27
Primary completion date: 2020-04-08
Completion date: 2020-08-26
Baseline population: The Full Analysis Set (FAS) includes all randomized participants who received at least 1 dose of the study drugs.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT02547922: Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
Official title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis
Acronym: TULIP-LN1
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 147.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-11-04
Primary completion date: 2019-11-26
Completion date: 2021-01-18
Baseline population: The full analysis set included all subjects who received at least one dose of study treatment and were analyzed according to randomized treatment.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
Clinical trial NCT04424641: A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Official title: First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors
Sponsor: Genmab (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was terminated due to MTD was reached
Enrollment: 48.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-07-15
Primary completion date: 2021-10-29
Completion date: 2021-10-29
Baseline population: Full analysis set included all participants who received at least 1 dose of study drug. Participants were classified according to the assigned dose level cohort.
Limitations and caveats: Upon review and evaluation of the overall safety profile and safety signals of GEN1044 during the dose-escalation part, the Safety Committee decided to stop further enrollment and the Sponsor decided to stop the compound development. Hence, the expansion part of the trial was never initiated, and while a majority of the pharmacokinetic (PK) samples from the dose-escalation part were quantified, the PK parameters were not calculated due to termination of the trial.
Clinical trial NCT02807467: Influence of Dexmedetomidine or Propofol on ICU Delirium
Official title: Comparison of Propofol and Dexmedetomidine to Treat Hyperactive and Mixed ICU Delirium - the Basel ProDex Randomized Trial
Sponsor: University Hospital, Basel, Switzerland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: insufficient recruitment over a long period
Enrollment: 37.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-01
Primary completion date: 2022-03-03
Completion date: 2023-02-11
Plan to share individual participant data: NO
IPD sharing description: anonymized data will be analyzed and published
Clinical trial NCT04354727: A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Official title: Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Sponsor: Ascentage Pharma Group Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-15
Primary completion date: 2022-12-15
Completion date: 2023-06-15
Plan to share individual participant data: NO
Clinical trial NCT03802747: Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
Official title: Phase I Study of Dual Immune Checkpoint Blockade (Anti-PD-L1 (Durvalumab) (MEDI4736) and Anti-CTLA4 (Tremelimumab) Plus Yttrium-90 (Y-90) Radioembolization & Stereotactic Body Radiation Therapy (SBRT) in Refractory Metastatic MSS (Microsatellite Stable) Colorectal Cancer With Liver Metastases
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: PI left the institution
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-31
Primary completion date: 2023-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT04833855: Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria
Acronym: INCEPTION
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 183.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-04-15
Primary completion date: 2022-12-20
Completion date: 2023-04-13
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT03690154: A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
Official title: A Phase 1, Multi-center, Open-label, Single-arm, Dose-escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML)
Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Despite demonstrated safety and tolerability the trial was terminated early due to program re-prioritization in light of the competitive landscape.
Enrollment: 67.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-23
Primary completion date: 2022-02-11
Completion date: 2022-02-11
Plan to share individual participant data: NO
Clinical trial NCT03193437: Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
Official title: A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
Acronym: SELECT
Sponsor: Georgetown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow Accrual
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-03
Primary completion date: 2020-07-27
Completion date: 2022-01-31
Plan to share individual participant data: NO
Clinical trial NCT03207334: iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
Official title: A Phase II, Open-Label Clinical Efficacy Study Defining Genomic Signatures That Correlate With Midostaurin Response in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Insufficient funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-30
Primary completion date: 2021-01-31
Completion date: 2022-01-31
Plan to share individual participant data: NO
Clinical trial NCT04345666: Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair
Official title: A Randomized, Blinded Controlled Trial to Determine if Testosterone Can Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair
Sponsor: Orthopedic Institute, Sioux Falls, SD (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Unable to obtain funding to complete the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-31
Primary completion date: 2022-08-31
Completion date: 2023-01-31
Plan to share individual participant data: NO
IPD sharing description: At this point there is no plan to share individual participant data with researcher external to this study
Clinical trial NCT04290858: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection
Official title: Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial
Acronym: NoCovid
Sponsor: Xijing Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: New coordinating center has been defined (Massachusetts General Hospital)
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-01
Primary completion date: 2021-03-01
Completion date: 2022-02-01
Clinical trial NCT03798080: Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Official title: A Randomized, 30-week, Active-controlled, Open-label, 2 Treatment-arm, Parallel Group, Multicenter Study Comparing Efficacy and Safety of iGlarLixi to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled on Basal Insulin With or Without Oral Antidiabetic Drug(s)
Acronym: Lixilan-L-CN
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 426.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-19
Primary completion date: 2020-12-01
Completion date: 2020-12-01
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04217057: Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
Official title: Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Insufficient funding/staff
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-07
Primary completion date: 2023-02-07
Completion date: 2023-02-07
Plan to share individual participant data: NO
Clinical trial NCT05012787: Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
Official title: A Double-Blind, Randomized, Controlled, Phase 3 Study to Evaluate the Safety and Immunogenicity of CpG 1018/Alum-adjuvanted SCB-2019 in Individuals Aged 18 and Above With Chronic Immune-Mediated Inflammatory Diseases
Acronym: COVID-19
Sponsor: Clover Biopharmaceuticals AUS Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was early terminated considering the inability to enroll the required study population.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-12
Primary completion date: 2022-03-30
Completion date: 2022-05-04
Clinical trial NCT03815292: Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
Official title: Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Study of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Subjects in Early Rehabilitation Period of Ischemic Stroke
Sponsor: Materia Medica Holding (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 276.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-19
Primary completion date: 2020-01-27
Completion date: 2020-01-27